CD8+ T cells are highly heterogeneous, and each subset plays a unique role in tumor immunity [40]; therefore, we assessed the frequency of CD226+ expressing cells among different CD8+ T cell subsets with respect to the disease stage. This evidence concerns the gene CD8A and neoplasm.